First Half 2026 Review: What’s Changing in Fertility Care? 5 Things That Might Affect You

The first half of 2026 brought several meaningful changes for the assisted reproductive technology (ART) industry. Some affect how much you pay. Some affect what treatments are available. Some affect how you think about the journey itself.

Here is a review of the key developments across policy, market, technology, and industry conferences. Let’s take a look at 5 things that might affect you here.

1. Policy: More Insurance Coverage Is Rolling Out

By the end of 2025, all 31 provinces in China had included ART in their basic medical insurance schemes. Shanghai, Zhejiang, Jiangxi, Qinghai, Shandong, and Xinjiang were among the latest to join.

The impact has been substantial. According to the National Healthcare Security Administration, over one million people accessed ART reimbursements in 2026, with a cumulative total of 3.24 million procedures covered, benefiting more than 1.6 million individuals.

Also, in the United States, California passed SB729, ensuring insurance coverage for IVF for single individuals.

What this means for you?

Reimbursement rates aren’t the same everywhere. Employee insurance typically covers 70% to 85% of costs, while resident insurance covers 50% to 70%. If your province is already covered, check exactly which procedures are included; they vary by region.

More provinces are likely to follow later this year if your province isn’t covered yet, the national government’s July 2026 National Health Plan explicitly calls for “strengthening medical expense coverage for appropriate ART services.” 

For international readers: If you’re traveling abroad for treatment, it’s worth checking whether your home country offers any reimbursements for overseas procedures. Some insurers cover treatment abroad, while others don’t.

1. Technology: Scientists Find Clear Answers on Why Embryos Stop Developing

The first half of 2026 saw a particularly strong wave of technological breakthroughs.

In June, a team from Tsinghua University published a landmark study in Cell. They captured the first complete footage of human embryo development over the 5 days before implantation; and identified two distinct reasons why embryos fail to reach blastocyst.

1. Early arrest (first 3 days) : Caused by faulty chromosome division during cell splitting. Think of it as the foundation not being laid correctly. When researchers used a PLK4 inhibitor, normal embryo rates jumped from 40% to 80% in preclinical models.

2. Late arrest (Day 4-5): Caused by protein shortage; not a chromosome issue, but a cellular production problem. The team has now identified a target for future drug screening.

What this means for you?

If you’ve had embryos that didn’t reach blastocyst, this research tells you importantly that it wasn’t your fault. 

Embryo development is biologically complex, and this study doesn’t offer an immediate clinical solution, but it gives scientists clear targets to work on. For patients, that’s a step toward more predictable outcomes in the future.

3. Market: Inflection Point Reached and The Numbers stand out

In March, Frost & Sullivan released its 2026 White Paper on the Development Status and Future Trends of China’s Assisted Reproductive Industry. Driven by rising infertility rates among older women and increased treatment penetration, the Chinese ART market is in a demand-release phase.

The market is projected to grow from RMB 23.5 billion in 2020 to RMB 63 billion in 2030, reaching RMB 86.5 billion by 2035.

At the same time, the National Health Commission reported that China now has 645 licensed ART institutions, with clinical success rates reaching international advanced levels.

What this means for you?

Fertility treatment is moving from “accessible to a few” to “accessible to more.” Penetration is growing, insurance is expanding, and centers are opening. That mean you have more options than families did five years ago. The key is finding the right option for you, not the one that worked for someone else.

There are now 645 licensed ART centers in China. However, fewer than 20 perform more than 5,000 egg retrieval cycles annually, just 3% of all centers.

If you’re choosing a center, this suggests volume matters for experience, but the right fit depends on your specific condition, not just the center’s size.

4. Mental Health Takes Center Stage  

The ASPIRE 2026 congress in Beijing (May 7-10) made mental health a core theme for the first time. Two numbers stood out:

1. A Korean study found that 88.9% of men with azoospermia experienced moderate to severe depressive symptoms.

2. A Japanese survey found that 64.7% of couples with non-obstructive azoospermia abandoned treatment entirely after failed sperm retrieval.

Data presented at the congress also showed that up to 60% of infertility patients face mental health challenges, but only about 20% seek professional psychological support.

What this means for you?

If you feel anxious, depressed, or exhausted on this journey, which is not mean you are weak.  It’s a normal response to an exceptionally difficult process, and you are not alone.

The data also suggests that structured couple counseling can help you make decisions with clearer thinking and better emotional preparation. If counseling is available to you, it’s worth considering as part of your toolkit.

5. A Quick Note for Patients Considering Treatment Abroad

California’s SB729 law (effective January 2026) requires large group health plans to cover infertility diagnosis and treatment, including IVF, for single individuals and LGBTQ+ families, not just married couples. That means if you hold a qualifying plan in California and you’re single, your IVF may be covered.

What this means for you:

If you already live or work in California, check whether your employer’s plan falls under SB729. If you’re traveling to California from abroad specifically for treatment, SB729 will not apply, most travel insurance does not cover IVF, but it does indicate a broader trend. The legal framework around IVF access is expanding in some parts of the world.

Looking Ahead

The first half of 2026 marked a clear turning point for the assisted reproductive industry. More insurance coverage, clearer science, and growing recognition of mental health needs. Fertility treatment is slowly becoming something more people can access.

Knowing that the industry is moving forward can give you confidence, but the decision is still yours to make, one step at a time.

For more information about fertility treatment options, email info@cefivf.com or visit our Contact page.

Note: This article is based on publicly available information as of July 2026 and is for informational purposes only.